December 21, 2021
Life Sciences
  • Biogen said that it has reduced the price of its Alzheimer’s drug Aduhelm by half. The moves follow a disappointing commercial launch of Aduhelm, as well as anger over the drug’s high price. Biogen also said it is planning a series of cost-cutting measures across the company next year that aim to save $500 million. (Articles here and here)